| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/24/2008 | WO2008011519A2 Amigo-2 inhibitors for treating, diagnosing or detecting cancer |
| 01/24/2008 | WO2008011157A2 Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| 01/24/2008 | WO2008011120A2 Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| 01/24/2008 | WO2008011107A2 Antagonists of protease activated receptor-1 (par1) |
| 01/24/2008 | WO2008011094A2 Cytokine induction of selectin ligands on cells |
| 01/24/2008 | WO2008011081A2 Wsx-1/p28 as a target for anti-inflammatory responses |
| 01/24/2008 | WO2008010980A2 Tat-049 and methods of assessing and treating cancer |
| 01/24/2008 | WO2008010556A1 Remedy for renal disease |
| 01/24/2008 | WO2008010478A1 Flagellin mutant vaccine |
| 01/24/2008 | WO2008010341A1 Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle |
| 01/24/2008 | WO2008009652A2 Vaccines for malaria |
| 01/24/2008 | WO2008009650A2 Vaccines for malaria |
| 01/24/2008 | WO2008009545A1 Anti-nkg2a antibodies and uses thereof |
| 01/24/2008 | WO2008009309A1 Influenza vaccine |
| 01/24/2008 | WO2008009062A1 Treatment for intimal hyperplasia and related conditions |
| 01/24/2008 | WO2007146414A3 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 01/24/2008 | WO2007139972A3 Expression of the cysteine protease legumain in vascular and inflammatory diseases |
| 01/24/2008 | WO2007137288A3 Methods and compositions for the treatment and prevention of staphylococcus aureus infections through interference with opuc operon interaction with trap |
| 01/24/2008 | WO2007122512A3 Separation of conjugated and unconjugated components |
| 01/24/2008 | WO2007117303A3 Combination vaccine comprising an attenuated bovine viral diarrhea virus |
| 01/24/2008 | WO2007116028A3 Conjugate vaccines |
| 01/24/2008 | WO2007105169B1 Vaccine against streptococcus agalactiae infection using native or recombinant s. agalactiae glyceraldheyde-3-phosphate dehydrogenase (gapdh) as a target antigen |
| 01/24/2008 | WO2007103322A3 Compositions that include hemagglutinin, methods of making and methods of use thereof |
| 01/24/2008 | WO2007061874A3 Methods and compositions for use in treating cancer |
| 01/24/2008 | WO2007050793A3 Methods and compositions for the treatment of marfan syndrome and associated disorders |
| 01/24/2008 | WO2007049265A3 Anti mineralocorticoid therapy of infection |
| 01/24/2008 | WO2006115843A3 Nipah virus vaccines |
| 01/24/2008 | WO2004069206A3 Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| 01/24/2008 | WO2004031361A3 Three-dimensional peripheral lymphoid organ cell cultures |
| 01/24/2008 | US20080021439 Intradermal cellular delivery using narrow gauge micro-cannula |
| 01/24/2008 | US20080021369 Methods and systems for toxin delivery to the nasal cavity |
| 01/24/2008 | US20080021201 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 01/24/2008 | US20080021196 Inhibitors of memapsin 2 and use thereof |
| 01/24/2008 | US20080021007 Substituted Porphyrins |
| 01/24/2008 | US20080020975 Galanin Receptors and Brain Injury |
| 01/24/2008 | US20080020969 36 Human Secreted Proteins |
| 01/24/2008 | US20080020965 Oxidative damage and protease activity resistance; catalytic efficiency; deep vein thrombosis, disseminated intravascular coagulation, acute coronary syndrome; targeting protein, that interacts with tissue factor or the factor VIIa/tissue factor complex |
| 01/24/2008 | US20080020045 Combination Degradable and Non-Degradable Matrices for Active Agent Delivery |
| 01/24/2008 | US20080020036 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 01/24/2008 | US20080020011 Therapeutic implant |
| 01/24/2008 | US20080020002 METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SERO TYPES A,C,Y, and W-135 |
| 01/24/2008 | US20080020001 Preparation of protective antigen |
| 01/24/2008 | US20080020000 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 01/24/2008 | US20080019999 Method of vaccinating subjects receiving immune modulating therapy |
| 01/24/2008 | US20080019998 Targeted gene delivery for dendritic cell vaccination |
| 01/24/2008 | US20080019995 Diagnostic Assay For Trypanosoma Cruzi Infection |
| 01/24/2008 | US20080019994 Immunization Against Chlamydia Infection |
| 01/24/2008 | US20080019993 Inhibition of tumour growth |
| 01/24/2008 | US20080019992 Antigen mimotopes and vaccine against cancerous diseases |
| 01/24/2008 | US20080019991 Carrier Conjugates Of Tnf-Peptides |
| 01/24/2008 | US20080019990 Therapeutic binding agents against MUC-1 antigen and methods for their use |
| 01/24/2008 | US20080019989 Immunity Adjuvant Containing a Complexed Metal Cation and Vaccine Containing Same |
| 01/24/2008 | US20080019988 Targeting of genetic vaccine vectors |
| 01/24/2008 | US20080019987 using a composition comprising a multimeric galectin-1 polypeptide to decrease inflammation of a tissue |
| 01/24/2008 | US20080019986 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
| 01/24/2008 | US20080019985 Oxidative damage and protease activity resistance; catalytic efficiency; deep vein thrombosis, disseminated intravascular coagulation, acute coronary syndrome; targeting protein, that interacts with tissue factor or the factor VIIa/tissue factor complex |
| 01/24/2008 | US20080019983 administering a conjugate of an isolated S. epidermidis antigen containing a 1,3-poly(glycerol phosphate) polymer chain and N-acetyl-glucosamine residues attached to the 2-position of the glycerol, and such antigen binds with antibodies to S. epidermidis to cure staphylococcal infected patient |
| 01/24/2008 | US20080019982 Administration of an activated form of ultra-low doses of antibodies to an antigen, obtained using homeopathic techniques; drug dependence/drug withdrawal; side effect reduction |
| 01/24/2008 | US20080019981 administering to proliferating cells in a mammal having a Ras-activated pathway a viruse selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus virus under conditions which result in lysis of neoplasmic cell |
| 01/24/2008 | US20080019980 modified adenovirus containing mutation in or lacks the virus associated RNA gene, modified HSV, vaccinia virus and parapoxvirus; Ras-activated pathway; neoplasm; immunosuppressant |
| 01/24/2008 | US20080019979 HERV-K Antigens, Antibodies, and Methods |
| 01/24/2008 | US20080019978 nicotinic receptor agonist useful for treating metabolic syndrome, dyslipidemia, cardiovascular diseases, disorders of the peripheral and central nervous system, hematological diseases, cancer, inflammation, respiratory diseases, gastrointestinal diseases, diabetes, and non-alcoholic fatty liver diseases |
| 01/24/2008 | US20080019977 administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist |
| 01/24/2008 | US20080019976 The antibodies bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo |
| 01/24/2008 | US20080019975 Novel Regimens for Treating Diseases and Disorders |
| 01/24/2008 | US20080019974 Immunoglobulins; cell line |
| 01/24/2008 | US20080019973 Methods for Treating Ocular Inflammation by Neutralizing Cxcl10 Activity |
| 01/24/2008 | US20080019972 Method for Amplifying Therapeutic Vaccine Activity |
| 01/24/2008 | US20080019971 36P6D5: secreted tumor antigen |
| 01/24/2008 | US20080019970 Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures |
| 01/24/2008 | US20080019969 Methods for Preventing, Postponing or Improving the Outcome of Invasive Spinal Procedures |
| 01/24/2008 | US20080019968 Detection, prevention and treatment of breast cancer |
| 01/24/2008 | US20080019967 Inflammatory mediator antagonists |
| 01/24/2008 | US20080019966 monoclonal antibodies, hybridomas; immunoglobulins, fab fragments |
| 01/24/2008 | US20080019965 Individualized anti-cancer antibodies |
| 01/24/2008 | US20080019964 Use of certain drugs for treating nerve root injury |
| 01/24/2008 | US20080019963 Antibodies, polypeptides and uses thereof |
| 01/24/2008 | US20080019962 Endotheliase-2 ligands |
| 01/24/2008 | US20080019961 Hedgehog signaling pathway antagonist cancer treatment |
| 01/24/2008 | US20080019960 Use of alefacept aka AMVIVE (reg) to treat herpes, HIV, hepatitis, papillomavirus, Epstein-Barr virus, cytomegalovirus in humans; includes co-infected individuals |
| 01/24/2008 | US20080019948 Process for Producing Engineered Targeted T Cell and Medicine |
| 01/24/2008 | US20080019944 Methods and Materials for Providing Cardiac Cells |
| 01/24/2008 | US20080019912 Glycoprotein 5 (GP5) and M protein of PRRSV linked by a disulfide bond gives rise to protective antigenic determinant (PAD polypeptide) that is used provide protection PRRSV; immunizing pigs |
| 01/24/2008 | US20080019910 Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors |
| 01/24/2008 | DE10121982B4 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation |
| 01/24/2008 | CA2829865A1 Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| 01/24/2008 | CA2658484A1 Compositions and methods for vaccinating against hsv-2 |
| 01/24/2008 | CA2658393A1 Human endogenous retrovirus polypeptide compositions and methods of use thereof |
| 01/24/2008 | CA2658352A1 Treatment for intimal hyperplasia and related conditions |
| 01/24/2008 | CA2658276A1 Antagonist antibody for the treatment of cancer |
| 01/24/2008 | CA2658082A1 Physiologically active polypeptide- or protein-encapsulating polymer micelles, and method for production of the same |
| 01/24/2008 | CA2657935A1 Antagonists of protease activated receptor-1 (par1) |
| 01/24/2008 | CA2657353A1 Vaccines for malaria |
| 01/24/2008 | CA2657279A1 Vaccines for malaria |
| 01/24/2008 | CA2655623A1 Anti-nkg2a antibodies and uses thereof |
| 01/23/2008 | EP1881327A2 Diagnosis and treatment of malignant neoplasms |
| 01/23/2008 | EP1881075A1 Retroviral vectors having a reduced recombination rate |
| 01/23/2008 | EP1881065A1 DINO polypetide |
| 01/23/2008 | EP1881007A1 LLR-J24 related proteins |
| 01/23/2008 | EP1880735A2 Vaccine |